Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2

With a fresh infusion of $140 million in series A funding, Ottimo will a advance a PD-1 x VEGFR-2 bifunctional antibody it believes will have a wider therapeutic window than PD-1 x VEGF bispecifics for solid tumors.

Growing interest in simultaneously targeting PD-(L)1 and VEGF has swollen the bispecific pipeline against the two targets. The goal of the drug class is to block angiogenesis specifically in the tumor, thereby reducing systemic side effects while also inducing antitumor immunity. ...